###
中国初级卫生保健:2020,34(11):19-20
←前一篇   |   后一篇→
本文二维码信息
码上扫一扫!
药品带量采购和一致性评价对利益相关者的影响
摘要
图/表
参考文献
相似文献
本文已被:浏览 4000次   下载 0
    
中文摘要: 摘 要 为缓解抗癌药品的短缺情况,减轻癌症患者的购药压力和经济负担。文章基于抗癌药品视角,运用利益相关者理论分析药品带量采购和仿制药一致性评价双重政策的实施对主要利益相关者的影响,发现癌症患者、政府、医院和仿制生产企业各利益相关者的合法性、权力性、紧迫性、损益及立场均有所不同。针对政府、医院、仿制药生产企业提出以下建议,政府应探索药品合理的定价机制和采购数量、及时公开信息、构建多国联盟的仿制药信息平台、严格监督市场;医院应积极响应政府号召、主动深化改革、探索激励机制;仿制药生产企业应抓住政策机遇、加强人才储备、注重科技进步。
Abstract:Abstract It aimed on providing references for alleviating the shortage of anti-cancer drugs, reducing the pressure of drug purchase and economic burden of cancer patients. Based on the perspective of anti-cancer drug, the stakeholder theory was used to analyze the impact of the implementation of the dual policies of the drug volume purchase and generic drug consistency evaluation on the main stakeholders, finding the legitimacy, power, urgency, gains and losses and position of each stakeholder that cancer patients, government, hospitals and generic anti-cancer drug production enterprises were different. It put forward the following suggestions for the government, hospitals, generic anti-cancer drug production enterprises. The government should explore justice price mechanism and quantity of procurement about drugs, open information timely, build anti-cancer drug message platform with many countries, supervise market strictly. The hospital should answer policies of the government actively, actively and deeply perform the reform, explore stimulating systems. The generic anti-cancer drug production enterprise should grasp opportunities of policies, strengthen the reserve of talents, and notice the progress of technology.
文章编号:3202006093     中图分类号:R197    文献标志码:
基金项目:
Author NameAffiliation
  
引用文本:


用微信扫一扫

用微信扫一扫